Skip to main content

Month: June 2020

Muscle Maker Grill Begins Construction on Third and Fourth Delivery-Only Ghost Kitchens in Chicago

Fast-Casual Brand Kicks Off Construction at Two Additional Ghost Kitchens in Downtown ChicagoBurleson, Texas, June 11, 2020 (GLOBE NEWSWIRE) — Muscle Maker Grill, Inc. (Nasdaq: GRIL) the parent company of Muscle Maker Grill & Healthy Joe’s, a fast-casual concept known for serving “healthier for you” meals, today announced that it has begun the construction phase at its third and fourth delivery-only ghost kitchens to open in the downtown Chicago market. The first two locations, which are now in the hiring and training phase are set to open in the coming weeks. The final kitchen out of the five Chicago locations is anticipated to open later this summer. The kitchens will feature menu items from both MMG Brands, Muscle Maker Grill and Healthy Joe’s. Individually packaged MMG meal plans will also be sold from all of the ghost...

Continue reading

Harpoon Therapeutics to Participate in Two Upcoming Virtual Conferences

SOUTH SAN FRANCISCO, Calif., June 11, 2020 (GLOBE NEWSWIRE) — Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced that Gerald McMahon, Ph.D., President and Chief Executive Officer, will participate in two upcoming virtual investor conferences:A fireside chat at the JMP Securities Hematology & Oncology Forum on Thursday, June 18, 2020 at 4:20 p.m. ET / 1:20 p.m. PT; and A fireside chat at the BMO 2020 Prescriptions for Success Healthcare Conference on Tuesday, June 23, 2020 at 2:30 p.m. ET / 11:30 a.m. PT.A live audio webcast of the fireside chats will be available in the Investors section of Harpoon Therapeutics’ website at www.harpoontx.com.About Harpoon TherapeuticsHarpoon Therapeutics is a clinical-stage immunotherapy company developing...

Continue reading

Radient Technologies Inc. Announces bioU Products Are Now Available at Medical Cannabis by Shoppers and Completion of Previously Announced Debt Settlement and Shares for Services

EDMONTON, Alberta, June 11, 2020 (GLOBE NEWSWIRE) — Radient Technologies Inc. (“Radient” or the “Company”) (TSX Venture: RTI; OTCQX: RDDTF), a global commercial manufacturer of high quality cannabinoid-based ingredients, formulations and products, announces that its recently launched bioU branded products are now available through Medical Cannabis by Shoppers, a subsidiary of Shoppers Drug Mart Inc.The bioU brand was created exclusively for Medical Cannabis by Shoppers and is now available across Canada. bioU products have been scientifically designed by Radient to provide a high quality, consistent, broad spectrum oil formulations to medical users. The first series of products to launch is the USpray line of extracts which come in a convenient, precise dosage oral spray format. A CBD dominate (1:20 ratio of THC:CBD) and balanced...

Continue reading

Crinetics Pharmaceuticals Confirms Completion for Half of the Enrolled Patients in the Ongoing Phase 2 ACROBAT Edge Clinical Trial for Paltusotine

28 patients have completed the open-label Edge trial measuring IGF-1 levels after 13 weeks of treatment when patients with acromegaly were switched to once daily oral paltusotine from commercially available depot injections of the peptide somatostatin receptor ligands (SRLs)Recruitment for the Edge and Evolve trials has been completed with 47 and 13 patients, respectively, and topline data is planned for the fourth quarter of 2020Management expects to use the results for the two trials to support the initiation of Phase 3 clinical development for paltusotine in the first half of 2021SAN DIEGO, June 11, 2020 (GLOBE NEWSWIRE) — Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related...

Continue reading

Otonomy to Present at Raymond James 2020 Human Health Innovation Conference

SAN DIEGO, June 11, 2020 (GLOBE NEWSWIRE) — Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that David A. Weber, Ph.D., president and chief executive officer, is scheduled to present a company overview at the Raymond James 2020 Human Health Innovation Conference (Virtual) on Thursday June 18, 2020 at 2:20 p.m. ET (11:20 a.m. PT).A live audio webcast of the presentations will be available through the Events page of the company’s website (www.otonomy.com). About OtonomyOtonomy is a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology. The company pioneered the application of drug delivery technology to the ear in order to develop products that achieve sustained drug exposure from a single...

Continue reading

The Lovesac Company to Present at the Oppenheimer 20th Annual Consumer Growth & E-Commerce Conference

STAMFORD, Conn., June 11, 2020 (GLOBE NEWSWIRE) — The Lovesac Company (Nasdaq:LOVE) today announced that the Company is scheduled to present at the Oppenheimer 20th Annual Consumer Growth & E-Commerce Conference, on Tuesday, June 16, 2020, at 2:00 p.m. Eastern Time.The fireside chat will be webcast live over the Internet and can be accessed on the Company’s Investor Relations website, investor.lovesac.com.About The Lovesac Company

Continue reading

CloudMD Announces Binding Term Sheet to Acquire Integrated Medical Clinic with 12 Physicians

Cashflow positive, generating C$3 million a year in revenueInnovative clinic using online booking and telemedicine, easily integrated into CloudMD’s Electronic Medical Records (EMR) softwareTeam of 24 healthcare professionals servicing over 60,000 patientsOffer specialist services including psychiatry and women’s healthVANCOUVER, British Columbia, June 11, 2020 (GLOBE NEWSWIRE) — CloudMD Software & Services Inc. (TSXV: DOC, OTCQB: DOCRF, Frankfurt: 6PH) (the “Company” or “CloudMD”), a telemedicine company seeking to revolutionize the delivery of healthcare to patients, announced today its intent to acquire a medical clinic based in Metro Vancouver, BC (the “Clinic”). The Company has signed a Binding Term Sheet (the “Term Sheet”) with the Clinic to acquire 100% of the business, assets and operations.The recent oversubscribed...

Continue reading

Primoris Services Corporation Announces Utility Awards Valued Over $45 Million

DALLAS, June 11, 2020 (GLOBE NEWSWIRE) — Primoris Services Corporation (NASDAQ Global Select: PRIM) (“Primoris” or “Company”) today announced three new utility awards valued over $45 million.  The contracts were secured by ARB Underground, part of the Utilities & Distribution segment. The awards are for four miles of gas pipe replacement work in Southern California and power line replacement work in Northern California.Work is scheduled to commence in the second quarter of 2020, and completion is expected in the second quarter of 2021.ABOUT PRIMORISFounded in 1960, Primoris, through various subsidiaries, has grown to become one of the leading providers of specialty contracting services operating mainly in the United States and Canada. Primoris provides a wide range of specialty construction services, fabrication, maintenance,...

Continue reading

HEXO Corp. reports third quarter fiscal 2020 financial results; Net Revenue Up 30% to $22.1 Million, Improved Operational Performance

Key Operating HighlightsGross Revenue increased 30% to $30.9M from $23.8M in Q2Net Revenue increased 30% to $22.1M from $17.0M in Q2Adult-use grams and gram equivalents sold increased 42% to 9,338 kg compared to Q2Gross Margins increased to 40%Operating expenses decreased to $26.8MClosed $46M public offering to enhance liquidityAdjusted EBITDA improved to ($4.3M) from ($8.5) in Q2; tracking towards positive adjusted EBITDA in the first half of fiscal 2021Announced expanded partnership with Molson Coors to explore US CBD market in ColoradoOTTAWA, June 11, 2020 (GLOBE NEWSWIRE) — HEXO Corp. (TSX: HEXO; NYSE: HEXO) (“HEXO” or the “Company”) today reported its financial results for the third quarter fiscal 2020 ended April 30, 2020. All amounts are expressed in Canadian dollars unless otherwise noted.“I’d like to take this...

Continue reading

HEXO Corp. publie les résultats financiers du troisième trimestre de l’exercice 2020 ; augmentation de 30 % des recettes nettes pour atteindre 22,1 M$ et amélioration de la performance opérationnelle

Faits saillants opérationnelsLes recettes brutes ont augmenté de 30 %, passant de 23,8 M$ au T2 à 30,9 M$Les recettes nettes ont augmenté de 30 %, passant de 17,0 M$ au T2 à 22,1 M$Les ventes de grammes et d’équivalents grammes pour adultes ont augmenté de 42 % par rapport au T2, pour atteindre 9 338 kgLes marges brutes ont augmenté pour atteindre 40%Les frais d’exploitation ont diminué pour s’établir à 26,8 M$Clôture d’un placement public de 46 M$ pour favoriser la liquiditéAmélioration du BAIIA rajusté passant de (8,5 M$) au T2 à (4,3 M$) ; évolution vers un BAIIA rajusté positif au cours du premier semestre de l’exercice 2021Annonce d’un partenariat élargi avec Molson Coors pour explorer le marché américain du CBD au ColoradoOTTAWA, 11 juin 2020 (GLOBE NEWSWIRE) — HEXO Corp. (TSX : HEXO ; NYSE : HEXO) (« HEXO »...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.